Gene: SLC35G2
Official Full Name: solute carrier family 35 member G2provided by HGNC
Gene Summary: Located in Golgi apparatus; plasma membrane; and synaptic vesicle membrane. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO25961 | SLC35G2 Knockout cell line (HeLa) | Human | SLC35G2 | 1:3~1:6 | Negative | Online Inquiry |
KO25962 | SLC35G2 Knockout cell line (HCT 116) | Human | SLC35G2 | 1:2~1:4 | Negative | Online Inquiry |
KO25963 | SLC35G2 Knockout cell line (HEK293) | Human | SLC35G2 | 1:3~1:6 | Negative | Online Inquiry |
KO25964 | SLC35G2 Knockout cell line (A549) | Human | SLC35G2 | 1:3~1:4 | Negative | Online Inquiry |
SLC35G2 Gene Knockout Cell Lines are specialized genetically modified cell models engineered to lack the SLC35G2 gene, which encodes a nucleotide sugar transporter involved in glycosylation processes. This product serves as a critical tool for researchers looking to explore the functional consequences of SLC35G2 deficiency on cellular processes, including glycoprotein synthesis, cell signaling, and metabolic pathways. By creating a controlled environment devoid of this gene, scientists can precisely investigate the role of SLC35G2 in various cellular functions and elucidate its implications in disease mechanisms.
The primary mechanism by which SLC35G2 Gene Knockout Cell Lines operate involves disrupting the typical glycosylation pathways, leading to altered cellular responses and functions. This unique modification allows researchers to study the downstream effects on protein integrity, stability, and function, thereby providing insights into how glycosylation influences cellular behavior and metabolism in both physiological and pathological contexts.
In scientific research and clinical applications, these knockout cell lines are invaluable. They facilitate the investigation of SLC35G2's role in diseases such as cancer, metabolic disorders, and neurodevelopmental conditions, where altered glycosylation profiles are often observed. The ability to replicate and manipulate these cellular models enhances the capacity for drug discovery and therapeutic development, offering a path toward innovative treatment strategies.
What sets our SLC35G2 Gene Knockout Cell Lines apart from traditional alternatives is their high specificity, reproducibility, and ease of use. Unlike conventional gene silencing approaches, these knockout models provide a permanent and stable genetic alteration, significantly reducing variability in experimental outcomes. This allows researchers to achieve greater accuracy and confidence in their findings.
Investing in SLC35G2 Gene Knockout Cell Lines empowers researchers and clinicians with a powerful instrument that fosters the understanding of complex biological systems. Our company boasts extensive expertise in developing cutting-edge genetic models, ensuring that our products are at the forefront of advancing biological and medical research. With our unwavering commitment to quality and innovation, we support the scientific community in their quest for knowledge and therapeutic breakthroughs.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.